Moreover, CD55-silenced tumors demonstrated higher degrees of cell death and tumor regression, inflammatory cell infiltrate, and fibrosis compared with nontargeted controls treated with cisplatin (Fig. 2 H). Here, CD55 is linked to neoplasm.